Report: Current Stock Reports

Posters on preclinical data on RVU305 and Synthetic Lethality Programs presented at the 2025 AACR Annual Meeting
April 25, 2025

Conclusion of a grant agreement with the Medical Research Agency
April 23, 2025

Decision not to enter into a Grant Agreement with the Medical Research Agency
April 9, 2025

Dosing of the first patient in the JASPIS-01 phase II study of dapolsertib (MEN1703/SEL24) for the treatment of patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
March 26, 2025

Preclinical data on synthetic lethality programs to be presented at the 2025 AACR Annual Meeting
March 26, 2025

Disclosure of delayed inside information regarding the decision to commence the collective redundancy process in the Company and the commencement of the consultation procedure with representatives of the Company’s employees
February 25, 2025

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline
February 25, 2025

Conclusion of funding agreement with the Małopolska Centre for Entrepreneurship
February 17, 2025

Recommendation of Ryvu’s project for funding by the Medical Research Agency
February 7, 2025

Recommendation of Ryvu’s project for funding by the Medical Research Agency
February 7, 2025

Termination of STING program under Research Collaboration Option and Exclusive License Agreement with BioNTech SE
January 30, 2025

Clinical update on RVU120 Phase II program
December 12, 2024

Dosing of the first patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)
December 5, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
December 2, 2024

Recommendation of Ryvu’s project for funding by the Małopolska Centre for Entrepreneurship
December 2, 2024

Publication dates for periodic reports in 2025
November 19, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
November 19, 2024

Clinical and preclinical data on RVU120, RVU305, WRN and synthetic lethality platform presented at the 2024 EORTC-NCI-AACR Symposium
October 23, 2024

Conclusion of an agreement in the area of operational execution of MEN1703 (SEL24) Phase II clinical trial in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
October 22, 2024

Clinical and preclinical data on RVU120, RVU305, WRN and synthetic lethality platform to be presented at the 2024 EORTC-NCI-AACR Symposium
October 9, 2024